Literature DB >> 10837392

Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy.

Y Mitamura1, S Takeuchi, A Matsuda, Y Tagawa, Y Mizue, J Nishihira.   

Abstract

AIMS: To assess the potential role of macrophage migration inhibitory factor (MIF) in the pathogenesis of proliferative diabetic retinopathy (PDR).
METHODS: MIF levels were assayed in the vitreous and paired serum samples of 73 consecutive patients with PDR (32 eyes) and macular hole or idiopathic epiretinal membrane (controls, 41 eyes). An enzyme linked immunosorbent assay technique was used to determine the concentrations of MIF.
RESULTS: The median vitreous level of MIF was 11.93 ng/ml (range 4.16-103.85) in the patients with PDR, and 1.79 ng/ml (undetectable-8.93) in the controls. Vitreous levels in eyes with PDR were significantly greater than those in the controls (p<0.0001). Vitreous levels were significantly higher than serum levels in eyes with PDR (p=0.0026). MIF levels were significantly higher in the vitreous of PDR patients with severe fibrous proliferation than in those with slight proliferation (p<0.05).
CONCLUSION: The results indicate increased levels of MIF in the vitreous of patients with PDR and a significant association between MIF levels and grades of fibrous proliferation, suggesting the possibility that MIF may play a part in the development of the proliferative phase of PDR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837392      PMCID: PMC1723498          DOI: 10.1136/bjo.84.6.636

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy.

Authors:  C Baudouin; D Fredj-Reygrobellet; W C Gordon; F Baudouin; G Peyman; P Lapalus; P Gastaud; N G Bazan
Journal:  Am J Ophthalmol       Date:  1990-12-15       Impact factor: 5.258

2.  Expression of macrophage migration inhibitory factor in rat retina and its immunohistochemical localization.

Authors:  A Matsuda; Y Tagawa; K Yoshida; H Matsuda; J Nishihira
Journal:  J Neuroimmunol       Date:  1997-07       Impact factor: 3.478

3.  C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy.

Authors:  C Capeans; M V De Rojas; S Lojo; M S Salorio
Journal:  Retina       Date:  1998       Impact factor: 4.256

4.  Cells of the immune system and their cytokines in epiretinal membranes and in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  S Tang; O F Scheiffarth; S R Thurau; G Wildner
Journal:  Ophthalmic Res       Date:  1993       Impact factor: 2.892

5.  Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders.

Authors:  A M Abu el-Asrar; J Van Damme; W Put; M Veckeneer; L Dralands; A Billiau; L Missotten
Journal:  Am J Ophthalmol       Date:  1997-05       Impact factor: 5.258

6.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

Authors:  M Bacher; C N Metz; T Calandra; K Mayer; J Chesney; M Lohoff; D Gemsa; T Donnelly; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.

Authors:  B R Bloom; B Bennett
Journal:  Science       Date:  1966-07-01       Impact factor: 47.728

8.  Activated T lymphocytes in epiretinal membranes from eyes of patients with proliferative diabetic retinopathy.

Authors:  S Tang; K C Le-Ruppert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

9.  Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy.

Authors:  K Hirase; T Ikeda; C Sotozono; K Nishida; H Sawa; S Kinoshita
Journal:  Arch Ophthalmol       Date:  1998-06

10.  Characterization of a lymphocyte factor which alters macrophage functions.

Authors:  C F Nathan; H G Remold; J R David
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

Review 2.  Diabetic Retinopathy: Vascular and Inflammatory Disease.

Authors:  F Semeraro; A Cancarini; R dell'Omo; S Rezzola; M R Romano; C Costagliola
Journal:  J Diabetes Res       Date:  2015-06-07       Impact factor: 4.011

3.  MIF Inhibitor ISO-1 Protects Photoreceptors and Reduces Gliosis in Experimental Retinal Detachment.

Authors:  Bongsu Kim; Rania Kusibati; Tyler Heisler-Taylor; Dimosthenis Mantopoulos; Jiaxi Ding; Mohamed H Abdel-Rahman; Abhay R Satoskar; Jonathan P Godbout; Sanjoy K Bhattacharya; Colleen M Cebulla
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

Review 4.  Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities.

Authors:  Robert Kleemann; Richard Bucala
Journal:  Mediators Inflamm       Date:  2010-02-09       Impact factor: 4.711

Review 5.  The role of MIF in type 1 and type 2 diabetes mellitus.

Authors:  Yuriko I Sánchez-Zamora; Miriam Rodriguez-Sosa
Journal:  J Diabetes Res       Date:  2014-01-02       Impact factor: 4.011

6.  Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry.

Authors:  Chin Soon Chee; Khai Meng Chang; Mun Fai Loke; Voon Pei Angela Loo; Visvaraja Subrayan
Journal:  PeerJ       Date:  2016-05-12       Impact factor: 2.984

7.  The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ajmal Ahmad; Mohammad Mairaj Siddiquei; Alexandra De Zutter; Eef Allegaert; Priscilla W Gikandi; Gert De Hertogh; Jo Van Damme; Ghislain Opdenakker; Sofie Struyf
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.